Thomas S Y Chan1, Joycelyn P Y Sim1, Yok-Lam Kwong2. Show Affiliations » 1. Department of Medicine, Queen Mary Hospital, Pokfulam, Road, Hong Kong. 2. Department of Medicine, Queen Mary Hospital, Pokfulam, Road, Hong Kong. ylkwong@hkucc.hku.hk.
Abstract
Entities: Chemical Disease
Mesh： See more » AdultAllograftsAntibodies, Monoclonal/therapeutic useAntineoplastic Agents, Immunological/therapeutic useAntineoplastic Combined Chemotherapy Protocols/therapeutic useCombined Modality TherapyFemaleHematopoietic Stem Cell TransplantationHumansNeoplasm Proteins/antagonists & inhibitorsNeoplasm Proteins/immunologyNivolumabPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapyPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma/therapyPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma/drug therapyPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma/therapyProgrammed Cell Death 1 Receptor/antagonists & inhibitorsProgrammed Cell Death 1 Receptor/immunologyProof of Concept StudyRecurrenceSalvage Therapy
Substances： See more » Antibodies, MonoclonalAntineoplastic Agents, ImmunologicalNeoplasm ProteinsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorNivolumab
Year: 2017 PMID： 28573313 DOI： 10.1007/s00277-017-3033-7
Source DB: PubMed Journal: Ann Hematol ISSN： 0939-5555 Impact factor: 3.673